Cogentum client Acrux today announced one of the biggest licensing  deals in Australian Biotech history. The deal with Eli Lilly ranks up there as one of the biggest outcomes for an Australian biotech. From the announcements you will see that this is a superb result for any Australian company seeking to license it’s technology.

Cogentum worked [...]

[Read more →]

The following piece appeared in September 28th edition of Bioshares #330, Australia’s leading analysis and commentary on the Biotech sector. It summarises our out take on the 2009 Bioshares conference held at Thredbo in September.

Don’t worry about your Technology, show me the Strategy

The 2009 Thredbo summit graphically illustrated why strategy is becoming increasingly more valuable [...]

[Read more →]

It would seem that the Australian Federal Government is still under intense pressure to follow the tired and hopeless old formula to solving the hospital bed crisis. The Australian Medical Association is pressuring the Government to “immediately spend at least $3 billion on 3,750 new public hospital beds and the staff and infrastructure to service [...]

[Read more →]

For some time we have heard media, political opposition parties and lobby and community groups complain about the hospital bed crisis.
Put simply, there are not enough Hospital beds for those patients who need them.
However,  the solution that is often put forward - building new hospitals, commissioning new wards, creating new beds is not the answer.
In [...]

[Read more →]